Trials / Unknown
UnknownNCT04520035
Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell
A Prospective, Single Arm, Single Center, Phase II Clinical Trial of Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, single arm, single center, phase II clinical trial of neoadjuvant chemotherapy with camrelizumab in locally advanced esophageal squamous cell,to evaluate the progression free survival
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | camrelizumab | Carilizumab 200 mg, every 3 weeks, 2 cycles.Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles |
| DRUG | Paclitaxel | Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles |
| DRUG | Neoadjuvant Chemotherapy | Neoadjuvant Chemotherapy |
Timeline
- Start date
- 2020-08-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2020-08-20
- Last updated
- 2020-08-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04520035. Inclusion in this directory is not an endorsement.